Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All evaluated claims under the requested warning topic (serious infections and malignancy) are supported by the provided HUMIRA label excerpts (Sections 5.1 and 5.2), with no detected contradictions or unsupported additions within the supplied claim set.
Category Scores
Accurate Statements
HUMIRA increases the risk of serious infections, which may lead to hospitalization or death, and opportunistic infections have been reported.
Supported by Section 5.1 Serious Infections (increased risk of serious infections; opportunistic infections reported).
HUMIRA should not be initiated in patients with an active infection, including localized infections.
Supported by Section 5.1 Serious Infections (do not initiate in patients with active infection including localized).
HUMIRA should be discontinued if a patient develops a serious infection or sepsis.
Supported by Section 5.1 Serious Infections (discontinue if serious infection or sepsis develops).
Patients 65 years of age and older, those with co-morbid conditions, and those taking concomitant immunosuppressants may be at greater risk of infection.
Supported by Section 5.1 Serious Infections (greater risk in these groups).
TNF blockers including HUMIRA are associated with malignancies, including lymphoma and other malignancies (some fatal), reported in children and adolescent patients.
Supported by Section 5.2 Malignancies (lymphoma and other malignancies including fatalities in children/adolescents).
Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported with TNF blockers including HUMIRA, with an aggressive and often fatal course.
Supported by Section 5.2 Malignancies (HSTCL described as rare, aggressive, often fatal; post-marketing cases).
Unsupported Statements
Contradictions
Important Omissions
The evaluation did not explicitly include the label text elements about (a) detailed list of opportunistic organisms, (b) guidance to close monitor for infection including possible TB development during and after treatment, and (c) latent TB testing prior to and during therapy (all present in Section 5.1).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Within the provided claim set, all statements about serious infections and malignancy risk are label-supported and no contradictions were identified. A few label monitoring/testing details present in the excerpts were not included in the evaluated claims, but they were not asserted incorrectly.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omitted label monitoring and latent TB testing instructions that are part of the Serious Infections warning excerpt.
Suggested Improvement
Include the label-supported statements regarding close monitoring for infection (including TB) during and after treatment and latent TB testing prior to and during therapy when discussing the Serious Infections warning.